FDA-cleared profile

TumorSight Viz

SimBioSys, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.

Clinical role
Breast MRI visualization, analysis, measurement, and concurrent physician review.
Images and patients
MRI · Breast; early-stage or locally advanced breast cancer
Key limitation
Keep in mind: The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Breast; early-stage or locally advanced breast cancer Input: Supported DICOM breast MRI studies, including dynamic contrast-enhanced series where labeled.
  • Who uses it?Intended users: Qualified radiologists and trained breast-imaging physicians.
  • What does the software produce?Output: Registered or subtracted series, measurements, three-dimensional views, and review displays.
  • What is its most important limitation?Key limitation: The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.

Clinical takeaway. Clinical role: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports performance testing on a validation dataset of 161 patients (163 samples) from 6 U.S. clinical sites, with ground truth from 7 U.S. board-certified radiologists. Tumor volume mean absolute error was 6.48 ± 12.67 cc (n=157); tumor segmentation volume Dice was 0.676 ± 0.289 and surface Dice 0.873 ± 0.264; all tests met the acceptance criteria. Measurements were also compared directly with the predicate device CADstream for 136 cases. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Breast MRI visualization, analysis, measurement, and concurrent physician review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported DICOM breast MRI studies, including dynamic contrast-enhanced series where labeled.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Registered or subtracted series, measurements, three-dimensional views, and review displays.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Breast-imaging and oncology workflows using supported breast MRI.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiologists and trained breast-imaging physicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports performance testing on a validation dataset of 161 patients (163 samples) from 6 U.S. clinical sites, with ground truth from 7 U.S. board-certified radiologists. Tumor volume mean absolute error was 6.48 ± 12.67 cc (n=157); tumor segmentation volume Dice was 0.676 ± 0.289 and surface Dice 0.873 ± 0.264; all tests met the acceptance criteria. Measurements were also compared directly with the predicate device CADstream for 136 cases. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DCE-MRI were obtained for one hundred sixty-one (161) patients (corresponding to 163 samples when accounting for bilateral disease) were obtained from six (6) clinical sites in the U.S. for use in validating the device." … "Seven (7) U.S. Board Certified radiologists reviewed 163 validation samples to establish the ground truth for the dataset according to predefined guidelines.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports performance testing on a validation dataset of 161 patients (163 samples) from 6 U.S. clinical sites, with ground truth from 7 U.S. board-certified radiologists. Tumor volume mean absolute error was 6.48 ± 12.67 cc (n=157); tumor segmentation volume Dice was 0.676 ± 0.289 and surface Dice 0.873 ± 0.264; all tests met the acceptance criteria. Measurements were also compared directly with the predicate device CADstream for 136 cases. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "DCE-MRI were obtained for one hundred sixty-one (161) patients (corresponding to 163 samples when accounting for bilateral disease) were obtained from six (6) clinical sites in the U.S. for use in validating the device." … "Seven (7) U.S. Board Certified radiologists reviewed 163 validation samples to establish the ground truth for the dataset according to predefined guidelines.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Tumor volume Dice coefficient mean

0.676 Dice coefficient

  • EndpointTumor volume segmentation agreement
  • PopulationIndependent validation set with usable volume comparisons
  • Tested versionTumorSight Viz configuration described in K231130

Tumor surface Dice coefficient mean

0.873 Dice coefficient

  • EndpointTumor surface segmentation agreement
  • PopulationIndependent validation set with usable surface comparisons
  • Tested versionTumorSight Viz configuration described in K231130

Validation sample count

163 samples

  • EndpointIndependent validation dataset size
  • PopulationBiopsy-proven early-stage or locally advanced breast cancer breast DCE-MRI from six U.S. sites
  • Tested versionTumorSight Viz configuration described in K231130

K231130 FDA evidence package for TumorSight Viz

  • DesignFDA 510(k) performance evaluation with separate training and tuning data and an independent validation set for the exact TumorSight Viz configuration.
  • PopulationBiopsy-proven early-stage or locally advanced breast cancer breast DCE-MRI samples from six U.S. validation sites.
  • Scopeexact submission
  • Tested versionTumorSight Viz configuration described in K231130
  • Samplen=163
  • Sites6
  • IndependenceSponsor or vendor study

K231130

The FDA package reports 161 patients and 163 validation samples; the promoted segmentation metrics use 157 samples with usable comparisons.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K231130 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported DICOM breast MRI studies, including dynamic contrast-enhanced series where labeled.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K231130: TumorSight Viz

  2. Routing

    Source context, not route validation: The FDA package describes DICOM MR input and a cloud platform accessed from an off-the-shelf computer.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K231130: TumorSight Viz

  3. AI processing

    Source context, not route validation: The FDA package describes a cloud-based platform; current hosting responsibility, contracts, availability, security, and site configuration remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K231130: TumorSight Viz

  4. Returned objects

    Source context, not route validation: Registered or subtracted series, measurements, three-dimensional views, and review displays.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K231130: TumorSight Viz

  5. Viewer/worklist/report

    Unresolved route: Registered or subtracted series, measurements, three-dimensional views, and review displays.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K231130: TumorSight Viz

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes a cloud-based platform; current hosting responsibility, contracts, availability, security, and site configuration remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes DICOM MR input and a cloud platform accessed from an off-the-shelf computer.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only qualified radiologists and trained breast-imaging physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K231130 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K231130 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA package describes a cloud-based platform; current hosting responsibility, contracts, availability, security, and site configuration remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes DICOM MR input and a cloud platform accessed from an off-the-shelf computer.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K231130 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The output is an aid to physician review and must not be the sole basis for patient management; exact breast MRI acquisition, cancer population, and validation limits apply.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. breast MRI analysis software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231130
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Breast; early-stage or locally advanced breast cancer
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-12-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K231130: TumorSight Viz

    U.S. Food and Drug Administration - Published 2023-12-26 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Tumorsight Viz model card (K231130)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K231130 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251766

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.

Modality
MRI
Anatomy
Breast
Decision
2025-07-08
FDA-cleared K243189

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.

Modality
MRI
Anatomy
Breast, including biopsy-proven breast tumors/findings.
Decision
2024-10-25
FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09
FDA-cleared K252922

Neosoma Brain Mets

Neosoma, Inc.

Authorized purpose: Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.

Modality
MRI
Anatomy
Brain; previously diagnosed brain metastases
Decision
2025-12-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history